20 results on '"Borba, Eduardo F."'
Search Results
2. Adrenal steroidogenesis and ovarian reserve in adult childhood-onset systemic lupus erytematosus patients
- Author
-
Lourenço, Daniela M. R., Araújo, Daniel B., Aikawa, Nadia E., Yamakami, Lucas Y. S., Borba, Eduardo F., Maciel, Gustavo A. R., Soares-Junior, Jose M., Baracat, Edmund C., Pereira, Rosa M. R., Bonfa, Eloisa, and Silva, Clovis A.
- Published
- 2021
- Full Text
- View/download PDF
3. Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2–3 mg/kg/day): 12-month prospective randomized controlled trial
- Author
-
Zanetti, Caio B., Pedrosa, Tatiana, Kupa, Léonard de V. K., Aikawa, Nadia E., Borba, Eduardo F., Vendramini, Margarete B. G., Silva, Clovis A., Pasoto, Sandra G., and Bonfa, Eloisa
- Published
- 2021
- Full Text
- View/download PDF
4. Time to diagnosis in systemic lupus erythematosus: Associated factors and its impact on damage accrual and mortality. Data from a multi-ethnic, multinational Latin American lupus cohort.
- Author
-
Nieto, Romina, Quintana, Rosana, Zavala-Flores, Ernesto, Serrano, Rosa, Roberts, Karen, Catoggio, Luis J, García, Mercedes A, Berbotto, Guillermo A, Saurit, Verónica, Bonfa, Eloisa, Borba, Eduardo F, Lavras Costallat, Lilian T, Da Silva, Nilzio A, Sato, Emilia I, Tavares Brenol, Joao C, Massardo, Loreto, Neira, Oscar J, Vázquez, Gloria, Guibert Toledano, Marlene, and Pascual-Ramos, Virginia
- Subjects
DELAYED diagnosis ,SYSTEMIC lupus erythematosus ,HEALTH insurance ,SYMPTOMS ,MORTALITY ,DIAGNOSIS - Abstract
Background: Systemic lupus erythematosus (SLE) often mimics symptoms of other diseases, and the interval between symptom onset and diagnosis may be long in some of these patients. Aims: To describe the characteristics associated with the time to SLE diagnosis and its impact on damage accrual and mortality in patients with SLE from a Latin American inception cohort. Methods: Patients were from a multi-ethnic, multi-national Latin-American SLE inception cohort. All participating centers had specialized lupus clinics. Socio-demographic, clinical/laboratory, disease activity, damage, and mortality between those with a longer and a shorter time to diagnosis were compared using descriptive statistical tests. Multivariable Cox regression models with damage accrual and mortality as the end points were performed, adjusting for age at SLE diagnosis, gender, ethnicity, level of education, and highest dose of prednisone for damage accrual, plus highest dose of prednisone, baseline SLEDAI, and baseline SDI for mortality. Results: Of the 1437 included in these analyses, the median time to diagnosis was 6.0 months (Q1–Q3 2.4–16.2); in 721 (50.2%) the time to diagnosis was longer than 6 months. Patients whose diagnosis took longer than 6 months were more frequently female, older at diagnosis, of Mestizo ethnicity, not having medical insurance, and having "non-classic" SLE symptoms. Longer time to diagnosis had no impact on either damage accrual (HR 1.09, 95% CI 0.93–1.28, p = 0.300) or mortality (HR 1.37, 95% CI 0.88–2.12, p = 0.200). Conclusions: In this inception cohort, a maximum time of 24 months with a median of 6 months to SLE diagnosis had no apparent negative impact on disease outcomes (damage accrual and mortality). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Predictors of severe hemolytic anemia and its impact on major outcomes in systemic lupus erythematosus: Data from a multiethnic Latin American cohort.
- Author
-
González, Luis Alonso, Alarcón, Graciela S., Harvey, Guillermina B., Quintana, Rosana, Pons-Estel, Guillermo J., Ugarte-Gil, Manuel F., Vásquez, Gloria, Catoggio, Luis J., García, Mercedes A., Borba, Eduardo F., Da Silva, Nilzio A., Tavares Brenol, João C., Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, Pascual-Ramos, Virginia, Amigo, Mary-Carmen, Barile-Fabris, Leonor A., García De La Torre, Ignacio, and Alfaro-Lozano, José
- Subjects
HEMOLYTIC anemia ,AUTOIMMUNE hemolytic anemia ,SYSTEMIC lupus erythematosus - Abstract
Objective: To determine the predictors of the occurrence of severe autoimmune hemolytic anemia (AIHA) and its impact on damage accrual and mortality in SLE patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Periodontitis treatment improves systemic lupus erythematosus response to immunosuppressive therapy
- Author
-
Fabbri, Cristiana, Fuller, Ricardo, Bonfá, Eloisa, Guedes, Lissiane K. N., D’Alleva, Paulo Sergio R., and Borba, Eduardo F.
- Published
- 2014
- Full Text
- View/download PDF
7. Hydroxychloroquine increased cholesterol transfer to high-density lipoprotein in systemic lupus erythematosus: A possible mechanism for the reversal of atherosclerosis in the disease.
- Author
-
Lang, Maria G, Vinagre, Carmen GC, Bonfa, Eloisa, Freitas, Fatima R, Pasoto, Sandra G, Brito, Tatiane S, Seguro, Luciana PC, Maranhão, Raul C, and Borba, Eduardo F
- Subjects
HDL cholesterol ,SYSTEMIC lupus erythematosus ,BLOOD lipids ,HYDROXYCHLOROQUINE ,BODY mass index ,ATHEROSCLEROSIS - Abstract
Introduction: The beneficial effect of hydroxychloroquine (HCQ) in decreasing LDL levels on Systemic Lupus Erythematosus (SLE) is well defined. The influence of this drug on HDL levels is still under debate and information about its effect on cholesterol reverse transport is lacking. Objective: To evaluate the effects of HCQ on HDL levels and the transfer of lipids to this lipoprotein in SLE. Methods: Nineteen SLE patients using only HCQ (SLE WITH HCQ), 19 SLE patients without any therapy (SLE WITHOUT THERAPY), and 19 healthy controls (CONTROL) were included. All three groups were premenopausal women age- and gender-matched. Serum lipids and apolipoproteins were determined by commercial kits. An in vitro transfer of four lipids (
14 C-Phospolipid,3 H-Cholesteryl ester,3 H-Triglyceride, and14 C-Unesterified cholesterol) from a radioactively labeled nanoemulsion donor to HDL was performed in all participants. Results: Groups had comparable mean age, weight, height, BMI(body mass index), and waist circumference (p >.05). Mean HDL levels were higher in SLE WITH HCQ group compared to SLE WITHOUT THERAPY(58.37 ± 14.04 vs 49.79 ± 8.0 mg/dL; p <.05) but lower than CONTROL (58.37 ± 14.04 vs 68.58 ± 9.99 mg/dL; p <.05). Total cholesterol (TC) and LDL levels were also significantly lower in SLE WITH HCQ compared SLE WITHOUT THERAPY(148.16 ± 16.43 vs 167.11 ± 30.18 mg/dL; p <.05, 75.05 ± 22.52 vs 96.05 ± 25.63 mg/dL; p <.05) and CONTROL (148.16 ± 16.43 vs 174.11 ± 23.70 mg/dL; p <.05, 75.05 ± 22.52 vs 88.53 ± 20.24 mg/dL; p <.05). The in vitro lipid transfer to HDL study revealed a significant difference among the three groups (p =.002) with a higher transfer of unesterified cholesterol(UC) in SLE WITH HCQ compared to SLE WITHOUT THERAPY(5.40 ± 1.05% vs. 4.44 ± 1.05%; p <.05). The latter was significantly decreased compared to CONTROL (5.40 ± 1.05% vs. 5.99 ± 1.71%; p <.05).The percentages of transfer of triacylglycerol (4.93 ± 0.69% vs. 4.50 ± 0.69% vs. 5.14 ± 1.01%; p =.054), esterified cholesterol (5.24 ± 0.70% vs. 4.96 ± 0.89% vs. 5.69 ± 1.27%; p =.079), and phospholipid (15.67 ± 1.03% vs. 15.34 ± 1.44% vs. 16.47 ± 1.89%; p =.066) were similar among groups. Conclusion: The present study is the first to demonstrate that HCQ promoted a higher transfer of unesterified cholesterol which may account for the increased HDL levels in lupus patients under HCQ. This desirable effect may underlie the reported reduced atherosclerosis in SLE. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
8. Impact of Distinct Therapies on Antibody Response to SARS‐CoV‐2 Vaccine in Systemic Lupus Erythematosus.
- Author
-
Yuki, Emily F. N., Borba, Eduardo F., Pasoto, Sandra G., Seguro, Luciana P., Lopes, Michelle, Saad, Carla G. S., Medeiros‐Ribeiro, Ana Cristina, Silva, Clovis A., de Andrade, Danieli C. O., Kupa, Leonard de Vinci K., Betancourt, Lorena, Bertoglio, Isabela, Valim, Juliana, Hoff, Camilla, Formiga, Francisco F. C., Pedrosa, Tatiana, Kallas, Esper G., Aikawa, Nadia E., and Bonfa, Eloisa
- Subjects
IMMUNOGLOBULINS ,COVID-19 vaccines ,SYSTEMIC lupus erythematosus ,UNIVARIATE analysis ,MYCOPHENOLIC acid - Abstract
Objective: To date, the only study that has assessed the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but the sample size precluded an accurate analysis of the effect of individual drugs. Therefore, we evaluated the immunogenicity of an inactivated SARS‐CoV‐2 vaccine (Sinovac‐CoronaVac) and the influence of different medications in SLE. Safety was also assessed. Methods: We conducted a prospective controlled study of 232 SARS‐CoV‐2–naive SLE patients and 58 SARS‐CoV‐2–naive controls who were vaccinated with 2 doses of Sinovac‐CoronaVac with a 28‐day interval (day 0/day 28 [D0/D28]). Immunogenicity analysis at D0/D28 and D69 included anti‐SARS‐CoV‐2 S1/S2 IgG seroconversion (SC) and neutralizing antibodies (NAb) positivity. The influence of individual drugs on immune response and safety was assessed. Results: Patients and controls were well balanced for age (P = 0.771). At D69, SLE patients showed a moderate SC (70.2% versus 98.1%; P < 0.001) and moderate frequency of NAb positivity (61.5% versus 84.6%; P = 0.002), although both frequencies were lower than in controls. Factors associated with lower SC in univariate analysis at D69 were prednisone use (odds ratio [OR] 0.215 [95% confidence interval (95% CI) 0.108–0.427], P < 0.001) and mycophenolate mofetil (MMF) use (OR 0.201 [95% CI 0.107–0.378], P < 0.001), whereas hydroxychloroquine (HCQ) use led to a 2.5 increase in SC (P = 0.011). SLE patients who were receiving HCQ monotherapy had similar SC to controls at D69 (100% versus 98.1%; P = 1.000). In multivariate analysis, prednisone and MMF use were independently associated with lower SC (P < 0.001) and NAb positivity (P < 0.001). Safety analysis revealed no moderate/severe adverse events. Conclusion: Sinovac‐CoronaVac has a moderate immunogenicity in SARS‐CoV‐2–naive SLE patients with an excellent safety profile. We further demonstrate that HCQ may improve SC, whereas prednisone and MMF had a major deleterious effect in vaccine response, reinforcing the need to investigate the role of temporary MMF withdrawal or a vaccine‐booster dose (ClinicalTrials.gov identifier: NCT04754698). [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria
- Author
-
Borba, Eduardo F., Guedes, Lissiane K., Christmann, Romy B., Figueiredo, Camille P., Gonçalves, Célio R., and Bonfá, Eloisa
- Published
- 2006
- Full Text
- View/download PDF
10. Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?
- Author
-
Signorelli, Flavio, Balbi, Gustavo Guimarães Moreira, Bonfá, Eloisa, Borba, Eduardo F, and Andrade, Danieli Castro de Oliveira
- Subjects
SYSTEMIC lupus erythematosus ,ANTIPHOSPHOLIPID syndrome - Abstract
Background: Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS. Objective: To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications. Results: Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35–53) and median PAPS disease duration of 13 years (8–19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients. Conclusion: ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus.
- Author
-
Barile-Fabris, Leonor A, Fragoso-Loyo, Hilda, Wojdyla, Daniel, Quintana, Rosana, Pons-Estel, Guillermo J, Catoggio, Luis J, García, Mercedes A, Saurit, Verónica, Drenkard, Cristina, Bonfa, Eloisa, Borba, Eduardo F, Sato, Emilia, Tavares Brenol, Joao C, Cavalcanti, Fernando, Da Silva, Nilzio A, Lavras Costallat, Lilian T, Guibert Toledano, Marlene, Massardo, Loreto, Neira, Oscar, and Cardiel, Mario H
- Subjects
LATIN Americans ,SYSTEMIC lupus erythematosus ,HEMOLYTIC anemia ,PROGNOSIS ,DISEASE duration ,DISEASE progression - Abstract
Introduction: Factors related to presentation of neuropsychiatric (NP) SLE manifestations, early in the course of the disease, and during follow up have not been clearly established. Purpose: To identify disease and non-disease related factors associated with NP manifestations in early SLE. Methods: We included 1193 patients from the GLADEL inception cohort free of NP involvement at cohort entry. We evaluated the association of demographic, clinical and laboratory data with NP involvement during follow-up. Statistical methods: Independent factors associated with NP involvement were identified using a multivariable Cox regression model. Results: Factors independently associated with NP manifestations were: mestizo ethnicity (HR 1.701, 95% CI 1.282–2.258, p = 0.0002), myalgias/myositis (HR 1.832, 95% CI 1.335–2.515, p = 0.0002), pneumonitis (HR 2.476, 95% CI 1.085–5.648, p = 0.0312), shrinking lung (HR 2.428, 95% CI 1.074–5.493, p = 0.0331) and hemolytic anemia (HR 1.629, 95% CI 1.130–2.347, p = 0.0089). Longer disease duration at cohort entry (13 to 24 months) was associated with a lower risk of developing NP manifestations (HR 0.642, 95% CI 0.441–0.934, p = 0.0206). Conclusions: Patients with myalgias/myositis, pneumonitis, shrinking lung and hemolytic anemia are at higher risk of NP involvement, whereas longer disease duration at cohort entry is associated with a lower risk of developing NP involvement. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis.
- Author
-
Pedrosa, Tatiana N, Pasoto, Sandra G, Aikawa, Nadia E, Yuki, Emily FN, Borba, Eduardo F, Filho, Julio CR Ferreira, Carricondo, Pedro C, Zanetti, Caio B, Conde, Paola G, Duarte, Nilo JC, Fontoura, Nicole, Romano, Paschoalina, Carvalho, Valdemir M, Silva, Clovis A, and Bonfa, Eloisa
- Subjects
LUPUS nephritis ,LIQUID chromatography-mass spectrometry ,HYDROXYCHLOROQUINE ,SYSTEMIC lupus erythematosus - Abstract
Objectives: It is unknown if hydroxychloroquine blood level dynamics impact flare rates in lupus nephritis patients. We prospectively evaluated hydroxychloroquine levels to determine which blood-based patterns are more associated with disease activity. Methods: In total, 82 lupus nephritis patients under a prescribed hydroxychloroquine dose of 4–5.5 mg/kg actual body weight (maximum 400 mg/day) for ≥3 months were evaluated at baseline and 7 months. Hydroxychloroquine blood levels were determined by liquid chromatography-tandem mass spectrometry. Flare was defined as increase ≥3 in the Systemic Lupus Erythematosus Disease Activity Index 2000 score and/or a change or increase in therapy. Results: Overall, 9/82(11%) patients had flares during follow-up and had lower baseline hydroxychloroquine blood levels than those without flares (220.4 (53.5–1471.1) vs. 1006.3 (53.5–2137.8) ng/ml, p = 0.013). The hydroxychloroquine blood level cut-off that best predicted flares was 613.5 ng/ml (odds ratio = 8.67, 95% confidence interval: 1.66–45.18, p = 0.006). For 77 (94%) patients, the 7-month hydroxychloroquine level dynamics was evaluated and revealed: 59/77 (77%) had a persistent pattern of adequate (41/77(53%)) or fluctuating (18/77 (23%)) levels, with a low and comparable risk of flares (2/41 (5%) vs. 1/18 (5%), p = 1.000). The remaining group had persistent low levels (18/77 (23%)) and their flare frequency was significantly higher than the adequate group (5/18 (28%) vs. 2/41 (5%), p = 0.023). The frequencies of adequate/inadequate hydroxychloroquine blood levels in patients were comparable at baseline and 7 months (McNemar's test, p = 0.480). Conclusion: We provide novel evidence that hydroxychloroquine blood-level patterns (persistently low, adequate, or intermittent) have distinct impacts on flare rates in lupus nephritis patients. These findings reinforce the need of routine hydroxychloroquine measurements to maintain the appropriate blood levels. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials.
- Author
-
Muniz, Luciana F., Pereira, Rosa M. R., Silva, Thiago F., Bonfá, Eloisa, Borba, Eduardo F., and Bonfá, Eloisa
- Subjects
CHLOROQUINE ,ANTIMALARIALS ,GLUCOCORTICOIDS ,PREDNISONE ,PROBABILITY theory ,SYSTEMIC lupus erythematosus ,PERIMENOPAUSE ,DISEASE prevalence ,METABOLIC syndrome ,CROSS-sectional method ,DISEASE complications ,PREVENTION ,THERAPEUTICS - Abstract
Objective: There are no data about the main factors associated with metabolic syndrome in young premenopausal systemic lupus erythematosus (SLE) patients. The aim of the study was to evaluate the frequency of metabolic syndrome and disease- or therapy-related factors in premenopausal young SLE patients.Methods: A total of 103 premenopausal SLE patients ages <40 years were selected and compared to 35 healthy premenopausal age-matched women. Metabolic syndrome was defined according to the 2009 Joint Interim Statement.Results: A higher frequency of metabolic syndrome (22.3% versus 5.7%; P = 0.03) was observed in the SLE group. Metabolic syndrome-SLE patients had higher SLE Disease Activity Index scores (mean ± SD 5.9 ± 7.6 versus 1.9 ± 2.7; P = 0.006), more frequently had previous renal disease (73.9% versus 51.2%; P = 0.05) and current renal disease (34.8% versus 10.0%; P = 0.008), and had higher current prednisone dose (median [range] 20 [0-60] versus 5 [0-60] mg/dl; P = 0.018) and cumulative prednisone dose (mean ± SD 41.48 ± 27.81 versus 24.7 ± 18.66 gm; P = 0.023) than those without metabolic syndrome. Chloroquine was less frequently used in metabolic syndrome-SLE patients (65.2% versus 90.0%; P = 0.008). In multivariate analysis, only current chloroquine use (prevalence ratio [PR] 0.29, 95% confidence interval [95% CI] 0.13-0.64) and cumulative prednisone were associated with metabolic syndrome (PR 1.02, 95% CI 1.01-1.04). Further estimated prevalence analysis identified the fact that antimalarial use promoted continuous decrease in the progressive metabolic syndrome prevalence associated with glucocorticoid cumulative dose.Conclusion: The prevalence of metabolic syndrome is high in premenopausal young adult SLE patients. Chloroquine has a protective effect on the prevalence of metabolic syndrome in these patients, and this benefit counteracts the deleterious effect of glucocorticoids in a dose-dependent manner. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
14. Circulating Follicular Helper-Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity.
- Author
-
Choi, Jin‐Young, Ho, John Hsi‐en, Pasoto, Sandra G., Bunin, Viviane, Kim, Sang Taek, Carrasco, Solange, Borba, Eduardo F., Gonçalves, Celio R., Costa, Priscila R., Kallas, Esper G., Bonfa, Eloisa, and Craft, Joseph
- Subjects
SYSTEMIC lupus erythematosus ,ACADEMIC medical centers ,ANALYSIS of variance ,STATISTICAL correlation ,RESEARCH funding ,STATISTICS ,T cells ,T-test (Statistics) ,DATA analysis ,SEVERITY of illness index ,DATA analysis software ,PROGNOSIS - Abstract
Objective To assess circulating follicular helper T (Tfh)-like CD4+ T cells in patients with systemic lupus erythematosus (SLE) and determine their relationship to disease activity. Methods Blood samples from patients with SLE, as well as blood samples from patients with Behçet's disease (BD) and healthy individuals as controls, were analyzed. In all samples, circulating Tfh-like cells were enumerated by flow cytometry, using, as markers, expression of CXCR5, inducible T cell costimulator (ICOS), and programmed death 1 (PD-1) protein, as well as secretion of interleukin-21 (IL-21). The frequency of circulating Tfh-like cells was compared to that of circulating plasmablasts (CD19+IgD−CD38+). In addition, the possible association of circulating Tfh-like cells with the SLE Disease Activity Index (SLEDAI) was evaluated. Results The subset of circulating Tfh-like T cells, identified as CXCR5
high ICOShigh PD-1high , was expanded in the blood of SLE patients compared to controls. Circulating Tfh-like cells were found to produce IL-21 and had lower expression of CCR7 as compared to that in circulating CXCR5high central memory T cells, thereby enabling their distinction. Expression of PD-1, but not ICOS or CXCR5, was significantly elevated in circulating Tfh-like cells from SLE patients compared to controls. PD-1 expression among CXCR5high circulating Tfh-like cells correlated with the SLEDAI, frequency of circulating plasmablasts, and anti-double-stranded DNA antibody positivity, but not with disease duration or past organ injury; rather, this cell profile appeared to be a reflection of current active disease. Conclusion Circulating Tfh-like cells are associated with disease activity in SLE, suggesting that their presence indicates abnormal homeostasis of T cell-B cell collaboration, with a causal relationship that is central to disease pathogenesis. These findings also suggest that circulating Tfh-like cells provide a surrogate for aberrant germinal center activity in SLE, and that their PD-1 expression offers a tool for measuring disease activity and monitoring the response to therapies. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
15. Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors—data from a multi-ethnic Latin American cohort.
- Author
-
García, Mercedes A., Alarcón, Graciela S., Boggio, Gabriela, Hachuel, Leticia, Marcos, Ana Inés, Marcos, Juan Carlos, Gentiletti, Silvana, Caeiro, Francisco, Sato, Emilia I., Borba, Eduardo F., Brenol, João C. Tavares, Massardo, Loreto, Molina-Restrepo, José Fernando, Vásquez, Gloria, Guibert-Toledano, Marlene, Barile-Fabris, Leonor, Amigo, Mary-Carmen, Huerta-Yáñez, Guillermo F., Cucho-Venegas, Jorge M., and Chacón-Diaz, Rosa
- Subjects
PREVENTION of heart diseases ,HEART disease risk factors ,ANTIMALARIALS ,ACADEMIC medical centers ,CONFIDENCE intervals ,MORTALITY ,MULTIVARIATE analysis ,PERICARDITIS ,SURVIVAL ,SYSTEMIC lupus erythematosus ,LOGISTIC regression analysis ,PROPORTIONAL hazards models ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio ,DISEASE complications ,THERAPEUTICS - Abstract
Objectives. The aim of this study was to assess the cumulative incidence, risk and protective factors and impact on mortality of primary cardiac disease in SLE patients (disease duration ≤2 years) from a multi-ethnic, international, longitudinal inception cohort (34 centres, 9 Latin American countries).Methods. Risk and protective factors of primary cardiac disease (pericarditis, myocarditis, endocarditis, arrhythmias and/or valvular abnormalities) were evaluated.Results. Of 1437 patients, 202 (14.1%) developed one or more manifestations: 164 pericarditis, 35 valvulopathy, 23 arrhythmias, 7 myocarditis and 1 endocarditis at follow-up; 77 of these patients also had an episode of primary cardiac disease at or before recruitment. In the multivariable parsimonious model, African/Latin American ethnicity [odds ratio (OR) 1.80, 95% CI 1.13, 2.86], primary cardiac disease at or before recruitment (OR 6.56, 95% CI 4.56, 9.43) and first SLICC/ACR Damage Index for SLE assessment (OR 1.31, 95% CI 1.14, 1.50) were risk factors for the subsequent occurrence of primary cardiac disease. CNS involvement (OR 0.44, 95% CI 0.25, 0.75) and antimalarial treatment (OR 0.62, 95% CI 0.44, 0.89) at or before recruitment were negatively associated with the occurrence of primary cardiac disease risk. Primary cardiac disease was not independently associated with mortality.Conclusion. Primary cardiac disease occurred in 14.1% of SLE patients of the Grupo Latino Americano de Estudio de Lupus cohort and pericarditis was its most frequent manifestation. African origin and lupus damage were found to be risk factors, while CNS involvement at or before recruitment and antimalarial treatment were protective. Primary cardiac disease had no impact on mortality. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
16. Evidence for cardiac safety and antiarrhythmic potential of chloroquine in systemic lupus erythematosus.
- Author
-
Alkmim Teixeira, Ricardo, Borba, Eduardo F., Pedrosa, Anísio, Nishioka, Silvana, Viana, Vilma S.T., Ramires, José A., Kalil-Filho, Roberto, Bonfá, Eloísa, and Martinelli Filho, Martino
- Abstract
Aims To perform a comprehensive evaluation of heart rhythm disorders and the influence of disease/therapy factors in a large systemic lupus erythematosus (SLE) cohort. Methods and results Three hundred and seventeen consecutive patients of an ongoing electronic database protocol were evaluated by resting electrocardiogram and 142 were randomly selected for 24 h Holter monitoring for arrhythmia and conduction disturbances. The mean age was 40.2 ± 12.1 years and disease duration was11.4 ± 8.1 years. Chloroquine (CQ) therapy was identified in 69.7% with a mean use of 8.5 ± 6.7 years. Electrocardiogram abnormalities were detected in 66 patients (20.8%): prolonged QTc/QTd (14.2%); bundle-branch block (2.5%); and atrioventricular block (AVB) (1.6%). Age was associated with AVB (P = 0.029) and prolonged QTc/QTd (P = 0.039) whereas anti-Ro/SS-A and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were not (P > 0.05). Chloroquine was negatively associated with AVB (P = 0.01) as was its longer use (6.1 ± 6.9 vs. 1.0 ± 2.5 years, P = 0.018). Time of CQ use was related with the absence of AVB [odds ratio (OR) = 0.103; 95% confidence interval (CI) = 0.011–0.934, P = 0.043] in multiple logistic regression. Holter monitoring revealed abnormalities in 121 patients (85.2%): supraventricular ectopies (63.4%) and tachyarrhythmia (18.3%); ventricular ectopies (45.8%). Atrial tachycardia/fibrillation (AT/AF) were associated with shorter CQ duration (7.05 ± 7.99 vs. 3.63 ± 5.02 years, P = 0.043) with a trend to less CQ use (P = 0.054), and older age (P < 0.001). Predictors of AT/AF in multiple logistic regression were age (OR = 1.115; 95% CI = 1.059–1.174, P < 0.001) and anti-Ro/SS-A (OR = 0.172; 95% CI = 0.047–0.629, P = 0.008). Conclusions Chloroquine seems to play a protective role in the unexpected high rate of cardiac arrhythmias and conduction disturbances observed in SLE. Further studies are necessary to determine if this antiarrhythmic effect is due to the disease control or a direct effect of the drug. [ABSTRACT FROM PUBLISHER]
- Published
- 2014
- Full Text
- View/download PDF
17. Anti-ribosomal P protein: a novel antibody in autoimmune hepatitis.
- Author
-
Calich, Ana L., Viana, Vilma S. T., Cancado, Eduardo, Tustumi, Francisco, Terrabuio, Débora R. B., Leon, Elaine P., Silva, Clovis A., Borba, Eduardo F., and Bonfa, Eloisa
- Subjects
CHRONIC active hepatitis ,AUTOIMMUNE disease diagnosis ,SYSTEMIC lupus erythematosus ,RIBOSOMAL proteins ,LIVER diseases ,DIAGNOSIS - Abstract
Background Autoantibodies to ribosomal P proteins (anti-rib P) are specific serological markers for systemic lupus erythematosus ( SLE) and are associated with liver involvement in this disease. The similarity in autoimmune background between autoimmune hepatitis ( AIH) and SLE-associated hepatitis raises the possibility that anti-rib P antibodies might also have relevance in AIH. Aims To evaluate the frequency and clinical significance of anti-rib P antibodies in a large AIH cohort. Methods Sera obtained at diagnosis of 96 AIH patients and of 82 healthy controls were tested for IgG anti-ribosomal P protein by ELISA. All of the sera were also screened for other lupus-specific autoantibodies, three patients with the presence of anti-ds DNA ( n = 1) and anti-Sm ( n = 2) were excluded. Results Moderate to high titres (>40 U) of anti-rib P antibody were found in 9.7% (9/93) of the AIH patients and none of the controls ( P = 0.003). At presentation, AIH patients with and without anti-rib P antibodies had similar demographic/clinical features, including the frequency of cirrhosis (44.4 vs. 28.5%, P = 0.44), hepatic laboratorial findings ( P > 0.05). Importantly, at the final observation (follow-up period 10.2 ± 4.9 years), the AIH patients with anti-rib P had a significantly higher frequency of cirrhosis compared with the negative group (100 vs. 60%, P = 0.04). Conclusion The novel demonstration of anti-rib P in AIH patients without clinical or laboratory evidence of SLE suggests a common underlying mechanism targeting the liver in these two diseases. In addition, this antibody appears to predict the patients with worse AIH prognoses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
18. Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?
- Author
-
Borba, Eduardo F., Saad, Carla G. S., Pasoto, Sandra G., Calich, Ana L. G., Aikawa, Nadia E., Ribeiro, Ana C. M., Moraes, Julio C. B., Leon, Elaine P., Costa, Luciana P., Guedes, Lissiane K. N., Silva, Clovis A. A., Goncalves, Celio R., Fuller, Ricardo, Oliveira, Suzimara A., Ishida, Maria A., Precioso, Alexander R., and Bonfa, Eloisa
- Subjects
- *
ANTIMALARIALS , *H1N1 influenza , *ACADEMIC medical centers , *ANTIRHEUMATIC agents , *BLOOD testing , *CLINICAL trials , *CONFIDENCE intervals , *FISHER exact test , *IMMUNIZATION , *IMMUNOSUPPRESSION , *HEALTH outcome assessment , *SYSTEMIC lupus erythematosus , *T-test (Statistics) , *EQUIPMENT & supplies , *TREATMENT effectiveness , *CASE-control method , *PREVENTION , *THERAPEUTICS - Abstract
Objective. To assess the efficacy and safety of pandemic 2009 influenza A (H1N1) in SLE under different therapeutic regimens.Methods. A total of 555 SLE patients and 170 healthy controls were vaccinated with a single dose of a non-adjuvanted preparation. According to current therapy, patients were initially classified as SLE No Therapy (n = 75) and SLE with Therapy (n = 480). Subsequent evaluations included groups under monotherapy: chloroquine (CQ) (n = 105), prednisone (PRED) ≥20 mg (n = 76), immunosuppressor (IS) (n = 95) and those with a combination of these drugs. Anti-H1N1 titres and seroconversion (SC) rate were evaluated at entry and 21 days post-vaccination.Results. The SLE with Therapy group had lower SC compared with healthy controls (59.0 vs 80.0%; P < 0.0001), whereas the SLE No Therapy group had equivalent SC (72 vs 80.0%; P = 0.18) compared with healthy controls. Further comparison revealed that the SC of SLE No Therapy (72%) was similar to the CQ group (69.5%; P = 0.75), but it was significantly reduced in PRED ≥20 mg (53.9%; P = 0.028), IS (55.7%; P = 0.035) and PRED ≥20 mg + IS (45.4%; P = 0.038). The concomitant use of CQ in each of these later regimens was associated with SC responses comparable with SLE No Therapy group (72%): PRED ≥20 mg + CQ (71.4%; P = 1.00), IS + CQ (65.2%; P = 0.54) and PRED ≥20 mg + IS + CQ (57.4%; P = 0.09).Conclusion. Pandemic influenza A H1N1/2009 vaccine response is diminished in SLE under immunosuppressive therapy and antimalarials seems to restore this immunogenicity.Trial registration. www.clinicaltrials.gov, NCT01151644. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
19. Mechanisms of dyslipoproteinemias in systemic lupus erythematosus.
- Author
-
Borba, Eduardo F., Carvalho, Jozelio F., and Bonfá, Eloísa
- Subjects
- *
DYSLIPIDEMIA , *SYSTEMIC lupus erythematosus , *HYPERLIPIDEMIA , *ATHEROSCLEROSIS treatment , *INFLAMMATION , *AUTOANTIBODIES , *HIGH density lipoproteins , *DIAGNOSIS , *THERAPEUTICS - Abstract
Autoimmunity and inflammation are associated with marked changes in lipid and lipoprotein metabolism in SLE. Autoantibodies and cytokines are able to modulate lipoprotein lipase (LPL) activity, a key enzyme in lipid metabolism, with a consequent “lupus pattern” of dyslipoproteinemia characterized by elevated levels of very low-density lipoprotein cholesterol (VLDL) and triglycerides (TG) and lower high-density lipoprotein cholesterol (HDL) levels. This pattern favors an enhanced LDL oxidation with a subsequent deleterious foam cell formation. Autoantibodies and immunocomplexes may aggravate this oxidative injury by inducing accumulation and deposition of oxLDL in endothelial cells. Drugs and associated diseases usually magnify the close interaction of these factors and further promote the proatherogenic environment of this disease. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
20. Penile anthropometry in adolescents and adults systemic lupus erythematosus.
- Author
-
Vecchi, Ana P., Borba, Eduardo F., Bonfá, Eloísa, Cocuzza, Marcelo, Pieri, Patrícia, Kim, Chong A, and Silva, Clovis A.
- Subjects
- *
SYSTEMIC lupus erythematosus - Abstract
An abstract of the conference paper "Penile anthropometry in adolescents and adults systemic lupus erythematosus," by Ana P. Vecchi, and colleagues, is presented.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.